EUS Guided HVA and PVA for Circulating Tumor DNA in Patients

Sponsor
Chinese University of Hong Kong
Study ID
NCT04782557
Status
Recruiting
Apply to this trial

Conditions

  • Circulating Tumor Cell
  • Gastrointestinal Cancer

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • EUS-guided portal vein and hepatic vein aspiration — DIAGNOSTIC_TEST
    EUS-guided portal vein and hepatic vein aspiration

Study Details

The discovery of cell-free circulating tumor DNA (crDNA) in blood and the maturation of technologies for ctDNA analysis have presented an attractive opportunity for minimally invasive "liquid biopsy" genomic diagnostics. The investigators plan to perform EUS-guided portal vein and hepatic vein aspiration in GI cancers patients. The aim of the current study is thus to examine the concentration of ctDNA in portal vein (EUS-guided PVA), hepatic vein (EUS-guided HVA) and peripheral blood to understand the first pass effect of the liver with gastrointestinal (GI) cancers, and the possibility of using ctDNA as a marker for preoperative staging, restaging after neoadjuvant chemotherapy, and monitoring for recurrence.

Key Dates

First listed
Mar 4, 2021
Start date
Jan 1, 2021
Status verified
Mar 2021
Primary completion
Jan 1, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: EUS-guided PVA and HVA
    Patient will undergo EUS-guided PVA and HVA

Primary Outcome Measure

Variant allelic fraction (expressed in %) of serum ctDNA from HVB, PVB and peripheral blood [ Time Frame: 3 months ]

Central Contacts

Related Studies